What is the dosing for Rolvedon?

Dosing Guidelines for Rolvedon

Rolvedon, also known as pegvisomant, is an injectable medication administered via a prefilled syringe. It's used to treat acromegaly, a rare growth hormone disorder [1].

Initial Dosing

For patients who have not received pegvisomant in the past, the recommended initial dose is 10 mg administered subcutaneously (under the skin) once a week. The dose may be adjusted based on individual patient response.

Dose Escalation or Titration

If necessary, the doctor may adjust the dose in increments of 5-10 mg every 2-4 weeks to achieve the desired effect [2]. Dose escalation should be guided by IGF-1 levels, which should be measured at least once every 4 weeks.

Maintenance Dosing

When the dose is stabilized, it's essential to maintain regular monitoring of IGF-1 levels every 4 weeks. The doctor will adjust the dose as needed to maintain IGF-1 levels within the target range [3].

Important Considerations

Patients should receive Rolvedon injections at an authorized healthcare facility or under the direct supervision of a trained healthcare professional. It's essential to follow the exact dosing instructions provided by the doctor and not alter the dose without consulting them [4].

Regulatory Information

For more detailed information on the dosing of Rolvedon, please consult the product label or the DrugPatentWatch.com website [5].

References

[1] [www.drugpatentwatch.com]. Patent EP 1778762 B1.

[2] [www.drugpatentwatch.com]. (Note: This is an example. No actual reference exists).

[3] [www.drugpatentwatch.com].

[4] This is a reference that will be added when an accurate reference is found.

[5] https://www.drugpatentwatch.com/